An assessment of physician reasons for prescribing Insulin Lispro 200 units/ml in Germany-Reference-Cited by-同舟云学术

An assessment of physician reasons for prescribing Insulin Lispro 200 units/ml in Germany

Published:2020-10-27 Issue:8 Volume:132 Page:727-736
ISSN:0032-5481
Container-title:Postgraduate Medicine
language:en
Short-container-title:Postgraduate Medicine

Author:

Chen Jieling¹^ORCID,Perez-Nieves Magaly¹,Piras De Oliveira Carolina¹,Spaepen Erik²,Osumili Beatrice³,Poon Jiat-Ling¹,Schloot Nanette⁴,Lara Nuria⁵,Garcia Alvarez Laura⁵,Roset Montserrat⁵^ORCID

Affiliation:

1. Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, USA

2. Global Medical Affairs, HaaPACS GmbH, Schriesheim, Germany

3. Global Patient Outcomes and Real World Evidence, International, Eli Lilly and Company Ltd, Windesham, Surrey, UK

4. Medical Affairs, Lilly Deutschland GmbH, Bad Homburg Vor Der Höhe, Germany

5. Real World Evidence Solutions, IQVIA, Real-World Evidence Solutions, Barcelona, Spain

Funder

Eli Lilly and Company

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00325481.2020.1805968

Reference33 articles.

1. Type 2 diabetes

2. Cosentino F, Grant P, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. 2019.

3. International Diabetes Federation. IDF Diabetes Atlas, 9th edition. Brussels, Belgium: 2019. Available at: https://www.diabetesatlas.org

4. A Review of Insulin for the Treatment of Diabetes Mellitus

5. High concentration insulin

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Profile of Patients with Diabetes Treated with Insulin Lispro 200 U/ml: A Real-World Study from Spain;Diabetes Therapy;2022-04-21